Scientists Develop Supercharged T Cells to Fight Prostate Cancer

Engineered 'catch bonds' allow T cells to latch onto cancer cells more effectively for a stronger, more targeted immune response.

Mar. 21, 2026 at 9:54am

Got story updates? Submit your updates here. ›

Researchers from UCLA, Stanford Medicine, the University of Utah, and Columbia University have engineered a new class of supercharged T cells that are stronger, longer-lasting, and more precise at killing prostate cancer cells. They introduced a natural "catch bond" - a fishhook-like interaction that strengthens when cells pull against each other - to allow T cells to latch onto cancer cells more effectively at the moment of attack, helping them recognize the tumor, stay engaged longer, and deliver a more powerful and targeted immune response without damaging healthy tissue.

Why it matters

T cells are a powerful weapon in the fight against cancer, but many of the proteins they target on cancer cells are also found in healthy tissue, leading the immune system to eliminate the strongest cancer-fighting T cells during development. This research aims to overcome this challenge by fine-tuning naturally occurring T cell receptors to strengthen their ability to recognize and destroy prostate cancer cells without attacking healthy tissue.

The details

Using a technique called catch bond engineering, the researchers "turbocharged" T cells by altering just one or two amino acids in the T cell receptor to strengthen the bonds with their cancer targets. This allowed the T cells to remain highly specific while dramatically boosting their cancer-killing ability. In laboratory experiments, the engineered T cells showed longer contact with cancer cells, greater secretion of tumor-killing molecules, and improved proliferation while resisting exhaustion. In mouse models, the engineered T cells delayed or completely halted tumor growth, while those receiving unmodified T cells showed little effect.

  • The study was published on March 21, 2026.

The players

Owen N. Witte

Co-senior author of the study, holds the Presidential Chair in Developmental Immunology in the Department of Microbiology, Immunology, and Molecular Genetics at UCLA and is a member of the UCLA Health Jonsson Comprehensive Cancer Center.

K. Christopher Garcia

Co-senior author of the study, the Younger Family Professor and Professor of Structural Biology at the Stanford School of Medicine and a Howard Hughes Medical Institute (HHMI) investigator.

Xiaojing Tina Chen

Co-first author of the study, a postdoctoral scholar in the Department of Molecular and Cellular Physiology at the Stanford School of Medicine and a recipient of the Walter Benjamin Fellowship awarded by the German Research Foundation.

Zhiyuan Mao

Co-first author of the study, a postdoctoral scholar in the Department of Microbiology, Immunology & Molecular Genetics and the Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA, and a recipient of the UCLA JCCC Postdoctoral Fellowship, the Prostate Cancer Foundation (PCF) Young Investigator Award, and a Cancer Research Institute (CRI) Irvington Postdoctoral Fellowship.

Brian D. Evavold

Senior author of the study, from the University of Utah School of Medicine.

Got photos? Submit your photos here. ›

What they’re saying

“By engineering catch bonds, we aim to benefit more patients by overcoming immune tolerance.”

— Owen N. Witte, Co-senior author

“Using advanced structural studies at atomic resolution, we were able to demonstrate how a tiny change, just one amino acid in the interface between a T cell receptor and a prostate cancer protein called PAP, can extend the bond lifetime, dramatically boosting the T cell's ability to kill tumors in living models.”

— Xiaojing Tina Chen, Co-first author

“This work shows that tumor control can be linked to a single molecular bond.”

— Zhiyuan Mao, Co-first author

“These findings suggest that catch bond engineering could be a generalizable strategy to enhance T cell therapies for many cancers.”

— K. Christopher Garcia, Co-senior author

“By creating T cells that are stronger, longer-lasting, and highly precise, the approach moves the field closer to safer and more effective adoptive cell therapies for patients.”

— Owen N. Witte, Co-senior author

What’s next

The researchers plan to further develop and test the engineered T cells in additional preclinical studies and eventually move towards clinical trials for prostate cancer patients.

The takeaway

This innovative approach to engineering T cell receptors using catch bonds represents a significant advancement in the field of cancer immunotherapy, offering the potential for more effective and safer treatments for prostate cancer and potentially other types of cancer as well.